TiilT is an innovative project funded by the European Union’s Horizon Europe Programme under Grant Agreement No. 101072435 coordinated by Pr David Klatzmann from Sorbonne University and Medical School. TiilT aims at developing a next generation immunotherapy based on Treg stimulation.

 

Regulatory T cells (Tregs) play a crucial role in controlling immune responses and are key targets for treating autoimmune and inflammatory diseases, including atherosclerosis, vasculitis and myocardial infarction. Low doses of Interleukin-2 (IL-2LD) can stimulate Tregs. Various forms of IL-2 are undergoing extensive clinical evaluation.

 

TiilT goal is to create a next generation IL-2 targeted to inflammatory sites (IL-2IT) and validate it for the treatment of inflammatory cardiovascular conditions, (more information available here).

 

Targeting inflammatory sites will be achieved by fusing IL-2 to antibodies (Abs) against oxidation specific epitopes (OSE), which serve as both universal markers and mediators of inflammation (more information available here).

 

Led by key experts in the field (click page 5), TiilT will validate the general concept of targeting therapeutic molecules to inflammatory sites and more specifically of targeting IL-2 as a treatment for inflammatory cardiovascular diseases, and beyond.